Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spontaneous regression of choroidal metastasis from renal cell carcinoma.
Rodriguez SM, Boldt HC, Sullivan HR, Rieth JM, Zakharia Y, Binkley EM. Rodriguez SM, et al. Among authors: zakharia y. Am J Ophthalmol Case Rep. 2023 Oct 20;32:101945. doi: 10.1016/j.ajoc.2023.101945. eCollection 2023 Dec. Am J Ophthalmol Case Rep. 2023. PMID: 37886109 Free PMC article.
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Loriot Y, et al. Among authors: zakharia y. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. N Engl J Med. 2019. PMID: 31340094 Clinical Trial.
Management of Fibroblast Growth Factor Inhibitor Treatment-emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Qi K, Akapame S, Triantos S, O'Hagan A, Loriot Y. Siefker-Radtke AO, et al. Among authors: zakharia y. Eur Urol Open Sci. 2023 Feb 16;50:1-9. doi: 10.1016/j.euros.2022.12.019. eCollection 2023 Apr. Eur Urol Open Sci. 2023. PMID: 37101768 Free PMC article.
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Talukder R, Bakaloudi DR, Makrakis D, Diamantopoulos LN, Enright T, Leary JB, Raychaudhuri R, Tripathi N, Agarwal N, Jindal T, Brown JR, Zakharia Y, Rey-Cárdenas M, Castellano D, Nguyen CB, Alva A, Zakopoulou R, Bamias A, Barrera RM, Marmolejo D, Drakaki A, Pinato DJ, Korolewicz J, Buznego LA, Duran I, Carballeira CC, McKay RR, Stewart TF, Gupta S, Barata P, Yu EY, Koshkin VS, Khaki AR, Grivas P. Talukder R, et al. Among authors: zakharia y. Clin Genitourin Cancer. 2024 Dec 2;23(1):102284. doi: 10.1016/j.clgc.2024.102284. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 39798390
Phase 2 Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1 Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.
Lee S, Hamid O, Jotte R, Zakharia Y, Medina T, Gillespie-Twardy A, Mehmi I, Chandra S, Watson G, Ward P, Chaney M, Lu H, Berndt J, O'Connor BP, Rathi K, Shaikh E, Cowey CL. Lee S, et al. Among authors: zakharia y. Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-1478. Online ahead of print. Clin Cancer Res. 2024. PMID: 39786430
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Jindal T, et al. Among authors: zakharia y. Eur Urol Oncol. 2024 Dec 20:S2588-9311(24)00289-X. doi: 10.1016/j.euo.2024.12.006. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39709257 Free article.
Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.
von Itzstein MS, Liu J, Mu-Mosley H, Fattah F, Park JY, SoRelle JA, Farrar JD, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Wakeland EK, Cole S, Bhalla S, Kainthla R, Puzanov I, Switzer B, Daniels GA, Zakharia Y, Shaheen M, Zhang J, Xie Y, Gerber DE. von Itzstein MS, et al. Among authors: zakharia y. JTO Clin Res Rep. 2024 Oct 19;6(1):100751. doi: 10.1016/j.jtocrr.2024.100751. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39619775 Free PMC article.
Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.
Berg SA, La Rosa S, Zhang T, Pierorazio PM, Albiges L, Beckermann KE, Campbell MT, Carlo MI, Coleman K, George DJ, Geynisman DM, Johnson R, Jonasch E, Maranchie JK, McGregor BA, Shapiro DD, Singer EA, Shuch BM, Stadler WM, Tannir NM, Zakharia Y, Vaishampayan UN, Thall PF, Msaouel P. Berg SA, et al. Among authors: zakharia y. Urol Oncol. 2024 Nov 4:S1078-1439(24)00701-4. doi: 10.1016/j.urolonc.2024.10.022. Online ahead of print. Urol Oncol. 2024. PMID: 39500687 Free article. Review.
125 results